Eris, Natco Launch Generic Semaglutide Brands as Patent Expires, Boosting Affordability
Eris, Natco Launch Generic Semaglutide Brands as Patent Expires, Boosting Affordability
- •Eris Lifesciences launched generic Semaglutide under the brand ‘Sundae’ in India, following the patent expiry of the molecule behind Ozempic and Wegovy.
- •Natco Pharma also announced the introduction of its generic Semaglutide Injection (multi-dose vials) under brand names Semanat and Semafull.
- •Both companies are offering multi-dose vial formats at highly accessible pricing, starting at Rs 1,290 per month, significantly improving affordability for diabetes and weight management.
- •Eris plans to introduce a pen-device version in April, while Natco's pen devices are expected next month, with varying strengths and price points.
- •Semaglutide, a GLP-1 receptor agonist, is a transformative therapy for Type 2 diabetes and weight management, offering strong outcomes in glycemic control and weight reduction.
